Investigators Review Marketed Adalimumab Biosimilars for Switching Differences

October 16, 2021

Investigators in Spain said they found no significant differences in outcomes for patients who switched from adalimumab originator to 1 of multiple adalimumab biosimilars.

FDA Grants Interchangeable Status for Boehringer Ingelheim's Adalimumab Biosimilar (Cyltezo)
The Top 5 Biosimilar Articles for the Week of October 11
Dose Adjustment, Infusion Interval Changes Hold Value for Patients With AS Treated With CT-P13
Biosimilars Forum Launches State-by-State Savings Calculator